Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Stock Price & Analysis
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — MoonshotScore 48/100 (Fair band), calculated Nov 18, 2026. Price $10.90 (0.00%), as of the Nov 19, 2026 trading session; market cap $265M.
Educational signal · not a buy or sell recommendation · How to read this
Drugs Made In America Acquisition Corp. Ordinary Shares · DMAA · NASDAQ
Drugs Made In America Acquisition Corp. is a blank check company focused on acquiring businesses through various methods like mergers and asset acquisitions. Operating within the financial services sector, it seeks to identify and capitalize on promising business opportunities.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Rising.
- Altman Z 18.63 · Piotroski F 3
- ROE 2.9% · ROA 4.1% · current ratio 0.02 · earnings yield 2.8% · free-cash-flow yield -0.1%
Holding back: a rich price, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 46 | Fair | |
| 45 | Weak | |
| 47 | Fair | |
| 47 | Fair | |
| 48 | Fair | |
| 48 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.90 | |
| Change on the day | 0.00% | |
| 52-week range | $10.32 – $10.91 | |
| Market capitalisation | $265M | |
| Price / earnings (trailing) | 61.83 | |
| Shares traded on the day | 1.8K |
Price & events
Other perspectives
Council score for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is listed on NASDAQ. It employs 2 people and is led by Roger Bendelac. The market values it at $265M.
What are the financial strengths and risks for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)?
Short answer · as of
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is a rich price, soft growth. The distress and quality screens read Altman Z 18.63 · Piotroski F 3. Trailing ratios: ROE 2.9% · ROA 4.1% · current ratio 0.02 · earnings yield 2.8% · free-cash-flow yield -0.1%.
How does Drugs Made In America Acquisition Corp. Ordinary Shares compare with its peers?
Short answer
Drugs Made In America Acquisition Corp. Ordinary Shares's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $10.84 Nov 19, 2026 | $276M | 59 5-pillar Nov 18, 2026 | |
| $10.13 Nov 18, 2026 | $311M | 59 5-pillar Nov 18, 2026 | |
| $10.10 Nov 19, 2026 | $292M | 57 5-pillar Nov 18, 2026 | |
| $10.46 Nov 19, 2026 | $303M | 50 5-pillar Nov 18, 2026 | |
| $10.08 Nov 19, 2026 | $227M | 50 5-pillar Nov 18, 2026 | |
| $10.74 Nov 19, 2026 | $255M | 49 5-pillar Nov 18, 2026 | |
| $10.30 Nov 19, 2026 | $231M | 49 5-pillar Nov 18, 2026 | |
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — this page | $10.90 | $265M | 48 |
| $10.48 Nov 19, 2026 | $355M | 48 5-pillar Nov 18, 2026 | |
| $10.49 Nov 19, 2026 | $327M | 47 5-pillar Nov 18, 2026 | |
| $33.50 Nov 19, 2026 | $252M | 47 5-pillar Nov 18, 2026 | |
| $10.97 Nov 19, 2026 | $287M | 47 5-pillar Nov 18, 2026 | |
| $10.38 Nov 18, 2026 | $283M | 30 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 2
- Purchases
- 8
- Sales
- 2
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DMAA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DMAA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)?
What Investors Ask About Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
These answers are editorial: 2 of these 9 answers are drawn from the DMAA research dossier (written Feb 8, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for DMAA?
DMAA carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is DMAA a good stock to buy?
Stock Expert AI does not rate DMAA buy, sell or hold. Drugs Made In America Acquisition Corp. Ordinary Shares carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the DMAA stock price today?
The last price recorded for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Drugs Made In America Acquisition Corp. Ordinary Shares do?
Drugs Made In America Acquisition Corp. (DMAA) operates as a blank check company, also known as a special purpose acquisition company (SPAC).
What are the main risks for DMAA?
Investing in Drugs Made In America Acquisition Corp. (DMAA) carries several inherent risks. The most significant risk is the failure to identify and acquire a suitable target company within the specified timeframe, which could lead to the liquidation of the SPAC and a loss of investment.
What are the key factors to evaluate for DMAA?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does DMAA data refresh on this page?
DMAA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven DMAA's recent stock price performance?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team (if applicable, details not provided). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DMAA overvalued or undervalued right now?
The trailing P/E of Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Feb 8, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com